Pegloticase
Horizon Therapeutics
[]
adding mtx to pegloticase for 52 wks in gout improved response rate by 30% reduced discontinuation rate by 40% greater resolution of tophi by 20% similar safety profile in mtx vs non-mtx groups
botson j, mirror rct #acr22 #acrbest 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach